Biomedical Research
Online ISSN : 1880-313X
Print ISSN : 0388-6107
ISSN-L : 0388-6107
Communications
Prevalence of low-penetrant germline TP53 D49H mutation in Japanese cancer patients
Ken YAMAGUCHIKenichi URAKAMITakeshi NAGASHIMAYuji SHIMODAShumpei OHNAMISumiko OHNAMIKeiichi OHSHIMATohru MOCHIZUKIKeiichi HATAKEYAMAMasakuni SERIZAWAYasuto AKIYAMAKouji MARUYAMAHirohisa KATAGIRIYuji ISHIDAKaoru TAKAHASHISeiichiro NISHIMURAMasanori TERASHIMATaiichi KAWAMURAYusuke KINUGASAYushi YAMAKAWATetsuro ONITSUKAYasuhisa OHDETakashi SUGINOIchiro ITOHiroyuki MATSUBAYASHIYasue HORIUCHIMaki MIZUGUCHIMutsumi YAMAZAKIKengo INOUEKimiko WAKAMATSUMisato SUGIYAMAKatsuhiko UESAKAMasatoshi KUSUHARA
Author information
JOURNALS FREE ACCESS

2016 Volume 37 Issue 4 Pages 259-264

Details
Abstract

Using whole exome sequencing data obtained from 1,685 Japanese cancer patients, we examined genetic variations of germline TP53 and found 10 types of non-synonymous single nucleotide variants. In the present study, we focused on 6 patients with germline D49H mutation located in the transactivation domain 2 of p53 protein, since the mutation seemed to be prevalent in cancer patients and to be pathogenic. According to the initial survey for family history of the proband with the germline TP53 D49H mutation, one osteosarcoma patient and his pedigree fulfill the criteria for Li-Fraumeni-like syndrome and the 2009 Chompret criteria for germline TP53 mutation screening. Since this patient possesses double germline mutations of TP53 D49H and A159D, further studies are required to evaluate contribution of the D49H mutation in this morbidity. The remaining 5 patients had family histories of cancer, but none fulfills the criteria either for the Li-Fraumeni/Li-Fraumeni-like syndromes or the 2009 Chompret criteria for germline TP53 mutation screening. It is possible to postulate that the germline TP53 D49H mutation is likely to be low-penetrant in some pedigrees. The present study also indicates that the survey for the germline TP53 mutation plays an important role in clinical practice as it will prevent mistaking cancer patients with unusual heredities for sporadic cases.

Information related to the author
© 2016 Biomedical Research Press
Previous article Next article
feedback
Top